Standard Biotools Inc (LAB) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Standard Biotools Inc. faces a significant risk of Nasdaq delisting after its shares traded below the $1.00 minimum bid price for 30 consecutive business days and it received a deficiency notice on April 20, 2026. Failure to regain compliance by the October 19, 2026 deadline, or to satisfy conditions for any extension, could severely reduce share liquidity and constrain its ability to raise capital or execute strategic transactions.
Overall, Wall Street has a Hold consensus rating on LAB stock based on 2 Holds.
To learn more about Standard Biotools Inc’s risk factors, click here.